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Abstract
Background: In chronic obstructive pulmonary disease (COPD), decreased progenitor cells and impairment of systemic
vascular function have been suggested to confer higher cardiovascular risk. The origin of these changes and their
relationship with alterations in the pulmonary circulation are unknown.
Objectives: To investigate whether changes in the number of circulating hematopoietic progenitor cells are associated with
pulmonary hypertension or changes in endothelial function.
Methods: 62 COPD patients and 35 controls (18 non-smokers and 17 smokers) without cardiovascular risk factors other than
cigarette smoking were studied. The number of circulating progenitors was measured as CD45+CD34+CD133+ labeled cells
by flow cytometry. Endothelial function was assessed by flow-mediated dilation. Markers of inflammation and angiogenesis
were also measured in all subjects.
Results: Compared with controls, the number of circulating progenitor cells was reduced in COPD patients. Progenitor cells
did not differ between control smokers and non-smokers. COPD patients with pulmonary hypertension showed greater
number of progenitor cells than those without pulmonary hypertension. Systemic endothelial function was worse in both
control smokers and COPD patients. Interleukin-6, fibrinogen, high sensitivity C-reactive protein, vascular endothelial
growth factor and tumor necrosis factor were increased in COPD. In COPD patients, the number of circulating progenitor
cells was inversely related to the flow-mediated dilation of systemic arteries.
Conclusions: Pulmonary and systemic vascular impairment in COPD is associated with cigarette smoking but not with the
reduced number of circulating hematopoietic progenitors. The latter appears to be a consequence of the disease itself not
related to smoking habit.
Citation: Pizarro S, Garcı´a-Lucio J, Peinado VI, Tura-Ceide O, Dı´ez M, et al. (2014) Circulating Progenitor Cells and Vascular Dysfunction in Chronic Obstructive
Pulmonary Disease. PLoS ONE 9(8): e106163. doi:10.1371/journal.pone.0106163
Editor: James West, Vanderbilt University Medical Center, United States of America
Received April 16, 2014; Accepted July 28, 2014; Published August 29, 2014
Copyright:  2014 Pizarro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work was supported by grants from the ‘‘Fondo de Investigacio´n Sanitaria, Instituto de Salud Carlos III’’ PI05/0244 and PI10/02175; ‘‘Fundacio´ la
Marato´ de TV3’’ (04310); SEPAR 2005; and the European Union (2005-018725/Pulmotension). S. Pizarro was the recipient of a predoctoral research fellowship from
Hospital Clı´nic. O. Tura-Ceide was the recipient of IDIBAPS-Biotrack postdoctoral fellowship and J. Garcı´a-Lucio was the recipient of a predoctoral research
fellowship (PFIS) from the ‘‘Instituto de Salud Carlos III.’’ The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: jbarbera@clinic.ub.es
Introduction
Chronic obstructive pulmonary disease (COPD) is associated
with alterations in pulmonary vessel structure and function, which
frequently result in pulmonary hypertension (PH), a major factor
associated with reduced survival [1]. Endothelial cell damage and
dysfunction produced by cigarette smoke or inflammatory
mediators appear to be at the origin of the remodeling process
of pulmonary vasculature and, hence, of PH [2]. The mechanisms
involved in pulmonary vascular remodeling are not fully
understood. Intimal hyperplasia, the most prominent feature of
pulmonary vascular remodeling, is produced by the proliferation
of poorly differentiated smooth muscle cells (SMCs) and the
deposition of collagen and elastic fibers [3]. The origin of these
cells and the causes of their uncontrolled proliferation are
uncertain.
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Circulating hematopoietic progenitor cells conform a popula-
tion of progenitor cells originated in the bone marrow with the
ability to be mobilized in response to vascular injury. These cells
play a key role in tissue repair and participate in the progression of
pre-existing lesions [4;5]. We have previously shown an increased
number of CD133+ progenitor cells within the wall of pulmonary
arteries of COPD patients [6]. CD133+ cells showed the capacity
to migrate from vessel lumen into the intima and differentiate into
SMCs [7]. This finding suggested that circulating bone marrow-
derived progenitor cells might be involved in pulmonary vessel
remodeling.
Patients with cardiovascular risk factors may show reduced
numbers of circulating progenitors and impaired endothelial
function in systemic arteries [8;9]. Both changes are associated
with shorter survival and increased number of cardiovascular
events [8;10;11].
Cardiovascular events are common in COPD patients. Recent
studies imply that COPD patients have lower circulating
progenitors [12–14] and dysfunctional systemic arteries [15–20].
This reduction of circulating progenitor cells in COPD patients
might lead to a lower repair capacity and consequently to an
altered vascular function [21–23]. Little is known about the origin
of these changes in COPD nor if they are associated with
alterations in the pulmonary circulation which may in turn
progress to PH, a factor also associated with poor prognosis [1].
We hypothesized that in COPD, the alterations in pulmonary
circulation are associated with changes in the number of
circulating progenitors by mechanisms similar to those involved
in the systemic circulation and also with changes in systemic vessel
function. Thereby, suggesting that similar mechanisms of vascular
impairment could occur in both systemic and pulmonary
circulations.
Accordingly, the present study aimed to investigate whether
COPD patients, without any cardiovascular risk factor other than
cigarette smoking, have different number of circulating hemato-
poietic progenitor cells. In addition, we aimed to study whether
this was associated with an altered endothelial function of systemic
arteries and/or with the presence of PH. Sex and age-matched
healthy subjects, non-smokers and current smokers, were used as
control groups.
Methods
Sixty-two COPD patients and 35 healthy controls (18 non-
smokers and 17 current smokers), aged between 50–75 years, were
enrolled in the study. Patients were recruited from the outpatient
clinic. The study was approved by the internal review board and
all subjects gave written informed consent. All subjects were free of
cardiovascular risk factors except cigarette smoking. Patients with
established cardiovascular, cerebral-vascular and/or metabolic
diseases, subjects under vasodilator, anti-lipidemic or anti-diabetic
therapy were excluded.
COPD was diagnosed according to current guidelines [24].
Patients were clinically stable at the time of the study without
exacerbation episodes or oral steroid treatment for the previous 4
months. All patients were on regular bronchodilator treatment and
most of them received inhaled corticosteroids. No patient was
receiving systemic steroids. Patients treated with long-term oxygen
were included. In control subjects, the absence of lung disease was
confirmed by clinical evaluation, chest radiograph and lung
function tests.
Measurements
All subjects underwent standard evaluation by means of medical
history, clinical examination, lung function tests, arterial blood
gases and electrocardiogram. COPD patients underwent addi-
tional Doppler echocardiography for the assessment of associated
PH. PH was considered when tricuspid regurgitant peak velocity
was.2.8 m/s [25], which is equivalent to a trans-tricuspid systolic
pressure gradient .31 mmHg. Three patients had PH confirmed
by right heart catheterization.
Interleukin-6 (IL-6), fibrinogen, C-reactive protein (hsCRP),
endothelin-1, nitrites/nitrates, vascular endothelial growth factor
(VEGF), angiopoietin-2 and brain natriuretic peptide (BNP) were
measured. In 31 COPD patients and 25 control subjects, tumor
necrosis factor-alpha (TNF-a) was additionally measured (see Data
S1).
Circulating progenitor cells
The number of circulating hematopoietic progenitors was
evaluated by flow cytometry using antibodies against CD45
(pan-leukocyte marker), CD133 (sub-population of hematopoietic
stem cells) and CD34 (mature and progenitor endothelial cells) as
previously described [26]. In brief, mononuclear cells (MNCs)
were isolated by Ficoll density gradient separation, washed once
with phosphate buffered saline (PBS) supplemented with 2% fetal
calf serum (FCS) and ressuspended at 26106 cells (control tube)
and at 46106 cells (sample tube). MNCs were stained and
analyzed for phenotypic expression of surface markers using pre-
conjugated anti-human monoclonal antibodies; anti-CD45-FITC,
anti-CD34-PECy7 and anti-CD133-PE. The fluorescence minus
one technique [27] was employed to provide negative controls.
After 45 minutes of incubation, cells were washed, ressuspended
into 500 ul of PBS+2% FCS and proceeded to flow-cytometric
analysis. 80,000 events were gated in the lymphocyte region
(Figure S1).
Endothelial function
Endothelial function was assessed by high resolution ultrasound
as the change in brachial artery diameter in response to reactive
hyperemia (flow-mediated dilation) [28]. Endothelium-indepen-
dent, nitroglycerine-mediated dilation was also measured. Addi-
tional details are provided in Data S1.
Statistical Analysis
Data are expressed as mean6SD for normally distributed data
or as median with interquartile range for skewed distributions.
Group comparisons were performed using one way ANOVA and
post hoc pairwise comparisons using the Student Newman-Keuls
test for normally distributed variables or the Kruskal-Wallis and
the Dunn’s test for non-normally distributed variables. Correla-
tions between variables were analyzed with Pearson’s or Spear-
man’s coefficient depending on data distribution. A p value,0.05
was considered statistically significant.
Results
Anthropometric, clinical and functional characteristics of
patients and control subjects are shown in Table 1. Groups were
well matched with respect to age, body mass and smoking status.
Patients with COPD had moderate to severe airflow limitation.
Thirty-seven of them (60%) were in spirometric GOLD [24] stage
II, 13 (21%) in stage III, and 12 (19%) in stage IV. They showed
air trapping, mild to moderate hypoxemia and PaCO2 within the
normal range. Half of the COPD patients and all control smokers
were current smokers. Eight patients were receiving long-term
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oxygen therapy. There were no differences in the Framingham
risk score between control subjects and COPD patients. Echocar-
diogram was performed in 57 patients with COPD. Twenty of
them had suspected PH as previously defined and 37 did not.
White blood cell counts were in the normal range in all subjects.
Yet, COPD patients and control smokers showed approximately
1.5 fold higher blood leukocyte, lymphocyte, neutrophil and
monocyte cell counts compared with control non-smokers. Red
blood cells and platelet counts were similar between groups.
Hemoglobin concentration was within the normal range in all
subjects (Table 1).
Circulating hematopoietic progenitor cells
Circulating hematopoietic progenitor cells were defined as
CD45+CD34+ or CD45+CD34+CD133+ cells. The number of
circulating progenitors corrected by the total number of leukocytes
was highly variable among individuals, particularly in control
subjects. The number of CD45+CD34+ cells were significantly
reduced in COPD patients compared with both smokers and non-
smokers control groups (Figure 1A). Similarly,
CD45+CD34+CD133+ labeled cells were significantly reduced in
COPD patients as compared with both control groups (Figure 1B).
The number of CD45+CD133+ labeled cells did not show any
significant difference between groups (data not shown). No
differences were seen in the number of CD45+CD34+ or
CD45+CD34+CD133+ between the non-smokers and the smokers
control groups.
The number of circulating CD45+CD34+CD133+ progenitors
in COPD patients was not related to the disease severity, as there
were no differences among patients with moderate, severe and
very severe COPD according to the spirometric GOLD stage
(Figure 2A). Furthermore, we did not find differences in the
number of circulating hematopoietic progenitors when comparing
patients with PaO2 or DLco above and below the median value
Table 1. Clinical characteristics, lung function, cardiovascular and laboratory measurements.
Control nonsmokers
(n = 18)
Control Smokers
(n = 17)
COPD Patients
(n = 62)
Age, years 5866 5968 6268
Male sex, n (%) 7 (39%) 12 (71%) 58 (94%)*
Body mass index (Kg/m2) 2563 2563 2663
Framingham risk score` 663 965 1266*
Current smokers, % 0 100* 47*
Smoking history, pack-years 0 41621* 60632*{
Expiratory carbon monoxide, ppm 0.960.6 2.961.7* 2.562.4*
FEV1, % predicted 10667 100612 53618*
{
FEV1/FVC 8265 7865 48613*
{
TLC, % predicted 9868 102616 109616*
RV, % predicted 102618 112618 168651*{
DLCO, % predicted 91611 79614 61619*
{
PaO2, mmHg 9768 86610 7268*
{
PaCO2, mmHg 3864 3563 3864
{
Systolic blood pressure, mmHg 115612 11369 120613
Diastolic blood pressure, mmHg 73610 7066 7269
Total Cholesterol, mg/dL 227634 195633* 207636*
Triglycerides, mg/dL 93641 96632 111648
HDL, mg/dL 61620 49616 53614
LDL mg/dL 148624 127630 132630
Glucose mg/dL 9369 89613 93620
Leukocyte count, 6109/L 5.4260.86 8.1261.52* 8.1061.82*
Lymphocyte count, 6109/L 1.5760.43 2.0760.69* 2.0360.65*
Monocyte count, 6109/L 0.2560.067 0.4260.15* 0.4660.14*
Neutrophils, 6109/L 3.2960.66 5.2561.60* 5.2361.52*
Red blood cells, 61012/L 4.7460.50 4.6460.40 4.7960.37
Hemoglobin (g/L) 143613 145617 149612
Platelet count, 6109/L 251646 290697 254661
Data are shown as mean 6 SD.
Definition of abbreviations: COPD: Chronic obstructive pulmonary disease; FEV1: post-bronchodilator forced expiratory volume in the first second; TLC: total lung
capacity; RV: residual volume; DLco: diffusing capacity of the lung for carbon monoxide; PaO2: partial pressure of arterial oxygen; PaCO2: partial pressure of arterial
carbon dioxide; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
*P,0.05 compared with control nonsmokers.
{P,0.05 compared with control smokers.
`The Framingham risk score can range from 26 to 19, with higher scores indicating greater cardiovascular risk.
doi:10.1371/journal.pone.0106163.t001
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Figure 1. Number of circulating hematopoietic progenitors cells in nonsmokers, control smokers and COPD patients. (A) Number of
CD45+CD34+ labelled cells, expressed as percent of lymphomonocytes. (B) Number of CD45+CD34+CD133+ labelled cells, expressed as percent of
lymphomonocytes. The box represents the interquartile range. The solid line indicates the median and the dashed line indicates the mean. The
whiskers extend from the box to the 90th and 10th percentiles. One-way analysis of variance and post hoc pairwise comparisons using the Dunn’s
test.
doi:10.1371/journal.pone.0106163.g001
Figure 2. Relationship between the number of circulating CD45+CD34+CD133+ labelled cells and COPD severity. (A) Patients grouped
according to the spirometric GOLD stage. (B) Patients grouped according to PaO2 value above or below the median value (70 mmHg). (C) Patients
grouped according to DLCO above or below the median value (60% predicted). (D) Patients grouped according to trans-tricuspid systolic pressure
gradient suggestive of pulmonary hypertension (.31 mmHg), assessed by Doppler echocardiography. The box represents the interquartile range.
The solid line indicates the median and the dashed line indicates the mean. The whiskers extend from the box to the 90th and 10th percentiles. One-
way analysis of variance post hoc pairwise comparisons using the Kruskal-Wallis and the Dunn’s test.
doi:10.1371/journal.pone.0106163.g002
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(Figure 2B, C). By contrast, COPD patients with increased trans-
tricuspid systolic pressure gradient suggestive of PH showed an
increased number of circulating progenitors compared with those
with normal gradient (Figure 2D).
Within the COPD group there were both current smokers and
ex-smokers. To evaluate whether smoking status could influence
circulating progenitor counts, group comparisons were repeated
excluding those COPD patients who were current smokers. The
re-analysis showed that COPD patients had lower levels of
circulating progenitors than controls (non-smokers and smokers)
irrespective of the smoking status (data not shown).
Endothelial function of systemic arteries
Baseline brachial artery diameter was greater in both COPD
patients and control smokers compared with non-smokers
(Table 2). Flow-mediated dilation of the brachial artery was
highly variable among individuals. Whereas the majority of non-
smokers showed a vasodilator response, both healthy smokers and
COPD patients had poor vasodilator responses and in a number of
cases a negative change (vasoconstrictor response). Compared with
non-smokers, flow-mediated dilation was equally significantly
reduced in both the COPD patients and the control smokers
(Table 2). To account for the differences in baseline vessel
diameter between groups, we calculated the ratio between flow-
mediated dilation and baseline brachial artery diameter, which is
an index of impaired vascular reactivity independent of vessel
diameter [29]. After this correction, both COPD patients and
control smokers continued to have lesser flow-mediated dilation
compared with non-smokers (Table 2).
Among COPD patients, those with suspected PH had lower
endothelium-dependent vasodilation than those without PH
(Figure 3A). In contrast, there were no differences in flow-
mediated dilation between COPD patients grouped according to
the spirometric GOLD stage (Figure 3B). Nitroglycerine admin-
istration produced significant dilation of the brachial artery in all
Table 2. Vascular reactivity of the brachial artery in the study population.
Control Nonsmokers
(n = 18)
Control Smokers
(n = 17)
COPD Patients
(n = 62)
Baseline brachial artery diameter, mm 4.0 (3.5 to 4.3) 4.4 (3.7 to 4.9) 4.5 (4.3 to 5.2)*
Flow-mediated dilation, % change
from baseline diameter
2.4 (1.1 to 4.1) 0.0 (20.8 to 1.6)* 0.9 (21.3 to 2.3)*
Flow-mediated dilation/Baseline
brachial artery diameter, %/mm
0.60 (0.30 to 1.10) 0.00 (20.17 to 0.35)* 0.22 (20.27 to 0.49)*
Nitroglycerine-mediated dilation, % 17.7 (15.3 to 20.6) 15.3 (13.4 to 21.5) 14.3 (9.7 to 19.8)
Hyperemia, % fraction of maximum
flow rate between the post-reactive
hyperemia and the basal rate,
normalized by heart rate
440 (348 to 572) 392 (315 to 611) 431 (369 to 571)
Data are shown as median (interquartile range).
*P,0.05 compared with control nonsmokers.
doi:10.1371/journal.pone.0106163.t002
Table 3. Vascular and systemic inflammatory markers in the study population.
Control Nonsmokers
(n = 18)
Control Smokers
(n = 17)
COPD patients
(n = 62)
IL-6, % detectable* 11 23 43
IL-6, pg/mL 35 (5 to 65) 6 (5 to 19) 8 (5 to 22)
VEGF, % detectable* 28 40 65
VEGF, pg/mL 38 (20 to 75) 43 (20 to 102) 60 (35 to 100)
hsCRP, mg/dL 0.12 (0.08 to 0.19) 0.24 (0.10 to 1.44) 0.45 (0.19 to 0.92){
BNP, pg/mL 17.5 (9.6 to 20.6) 20.5 (13.0 to 25.2) 21.9 (8.4 to 29.4)
Fibrinogen, g/L 3.3 (2.8 to 3.8) 3.9 (3.3 to 4.2){ 4 (3.6 to 4.9){
Nitrites/nitrates, nMol/mL 17.9 (13.9 to 27.3) 21.4 (19.4 to 27.8) 22.3 (15.2 to 32.5)
Endothelin-1, pmol/L 5.7 (4.6 to 7.4) 5.7 (4.4 to 6.4) 5.1 (4.0 to 7.0)
Angiopoietin-2, pg/mL 408 (263 to 486) 434 (390 to 649){ 406 (333 to 528)
TNF-a, pg/mL` 4.0 (3 to 5) 5.5 (5 to 6) 6.0 (5 to 7){
Data are shown as median (interquartile range).
Definition of abbreviations: IL-6: Interleukin-6; VEGF: vascular endothelial growth factor; hsCRP: high sensitive C-reactive protein; BNP: Brain natriuretic peptide; TNF-a:
tumour necrosis factor a.
*p,0.05 Chi-square.
{P,0.05 compared with control nonsmokers.
`TNF-a was measured in 23 control subjects (13 nonsmokers and 10 smokers) and 30 COPD patients.
doi:10.1371/journal.pone.0106163.t003
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subjects without significant differences between groups, although it
was slightly lower in the COPD group (P= 0.06) (Table 2).
Inflammatory and vascular markers
Compared with control non-smokers, COPD patients had
higher plasma levels of fibrinogen and VEGF, as well as higher
serum levels of IL-6, TNF-a and hsCRP. Control smokers had
higher levels of angiopoietin-2, fibrinogen, TNF-a and IL-6 than
non-smokers, without differences with COPD patients (Table 3).
No differences in the serum or plasma levels of the different
biomarkers were found in COPD patients according to the
severity of airflow obstruction or the presence/absence of PH.
Relationship among circulating progenitor cells, systemic
endothelial function, lung function and vascular
biomarkers
In the entire study population, we observed statistically
significant correlations between the number of circulating
progenitor cells and FEV1, DLco and PaO2 (r = 0.21, 0.23 and
0.28, respectively, P,0.05 each) consistent with the differences
between groups. We did not observe any significant correlation
between the number of circulating progenitors and flow-mediated
dilation in the whole series. However, within the COPD group the
number of circulating progenitors was inversely related to the flow-
mediated dilation of the brachial artery (Figure 4). Patients with
worse endothelial function had greater numbers of circulating
progenitors. The levels of inflammatory and vascular biomarkers
were not related either to circulating progenitors or systemic
endothelial function both in the entire study population and in the
COPD group.
Discussion
Results of the present study show that patients with COPD,
without cardiovascular comorbidities and risk factors other than
cigarette smoking, have reduced numbers of
CD45+CD34+CD133+ circulating progenitor cells compared with
both smokers and non-smokers control groups and an impaired
endothelial function in systemic arteries. Among COPD patients
the highest numbers of circulating hematopoietic progenitor cells
were observed in those who had poorer systemic endothelial
function and increased pulmonary arterial pressure. Healthy
smokers also showed systemic endothelial dysfunction, but in
Figure 3. Relationship between endothelial function, assessed by flow-mediated dilation, of the brachial artery and COPD severity.
(A) Patients grouped according to trans-tricuspid systolic pressure gradient suggestive of pulmonary hypertension (.31 mmHg), assessed by
Doppler echocardiography. (B) Patients grouped according to the spirometric GOLD stage. The box represents the interquartile range. The solid line
indicates the median and the dashed line indicates the mean. The whiskers extend from the box to the 90th and 10th percentiles. One-way analysis of
variance and post hoc pairwise comparisons using the Dunn’s test.
doi:10.1371/journal.pone.0106163.g003
Figure 4. Inverse correlation between progenitor cells and endothelial function. Inverse relationship between the number of circulating
CD45+CD34+CD133+ progenitor cells and the endothelial function, assessed by flow-mediated dilation, of the brachial artery in patients with COPD
(r =20.27, P,0.05).
doi:10.1371/journal.pone.0106163.g004
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contrast to COPD patients the number of circulating progenitors
did no differ from non-smokers.
In COPD, previous studies have investigated the number of
endothelial progenitor cells [12;14;30–32]. While most of the
studies indicate lower levels of circulating progenitor cells in
COPD patients compared with controls, others do not [30]. This
discrepancy between results most probably is due to significant
methodological differences between laboratories and failure to
reliably match for cardiovascular risk factors, gender and age [30].
In this study, we aimed to exclude subjects with cardiovascular risk
factors and separate healthy non-smokers from healthy smokers.
These grouping criteria are significant since it has been shown that
these factors are associated with a reduction of circulating
progenitors and could provide false positive results [8;9].
It is of note that all COPD patients were current or former
smokers. Nevertheless, smoking status did not seem to account for
the reduction in circulating progenitors since smokers without
COPD had greater number of progenitor cells than in COPD
patients and similar to those observed in non-smokers. The effect
of cigarette smoking on progenitor cells is controversial. While
some studies have reported a significant increase when incubated
in vitro with nicotine [33] or increased circulating number after
second hand smoke exposure [34], others have reported reduced
circulating progenitor cells in healthy smokers [35]. Our
observation of similar numbers of circulating progenitors in
healthy smokers and in non-smokers suggests that in the absence
of other cardiovascular risk factors (namely diabetes, hypercho-
lesterolemia or systemic arterial hypertension) cigarette smoking
does not seem to alter them. Accordingly, our results indicate that
in COPD the reduction in circulating progenitor cells is
independent of the smoking habit and appears to be related to
the disease itself.
The mechanisms by which circulating hematopoietic progenitor
cells may be reduced in COPD are not apparent. In contrast to
previous results [12;14], in our study the number of circulating
hematopoietic progenitor cells was not related to disease severity,
as assessed either by spirometric GOLD staging or by conven-
tional lung function measurements (FEV1, DLco, PaO2). Only the
presence of suspected PH was associated with a slight increase in
CD45+CD34+CD133+ cells. Several hypotheses have been sug-
gested to explain the reduction of progenitor cells in COPD:
impairment of the bone marrow to produce and release progenitor
cells [14], recruitment of circulating progenitors in injured lung
vessels [6;36–38], increased apoptosis [12], and the effect of
inflammatory or angiogenic mediators [39]. In our series, COPD
patients had normal peripheral blood cell counts. Even though,
white blood cell counts were higher in the COPD group than in
control non-smokers. Accordingly, bone marrow impairment does
not seem to account for the observed reduction in circulating
progenitors. We did not test for the presence of apoptosis, thus we
cannot rule out the suggestion that the decrease of circulating
progenitor cells could result from increased cell death rate due to
apoptosis [12]. In a similar way, we cannot disregard that
circulating progenitor cells could be recruited in injured vessels. In
fact, our group has previously demonstrated the presence of cells
expressing CD45 and CD133 markers in the wall of pulmonary
arteries in COPD patients [6], potentially suggesting recruitment
of bone marrow-derived progenitor cells that might eventually
contribute to an ongoing process of endothelium repair or be
involved in the pathogenesis of vessel remodelling [6]. Fadini et al
[12], reported an inverse relationship between PaO2 and
circulating progenitor cells, suggesting that hypoxia could stimu-
late progenitor cell mobilization from the bone marrow and their
localization at the damaged pulmonary endothelium. In our study
we did not observe any relationship between the number of
circulating progenitors and PaO2. Yet, patients with suspected PH
showed greater numbers of circulating progenitor cells than those
with systolic PAP within the normal range [25], a finding that
would be in favor that damaged pulmonary endothelium could
stimulate the mobilization of progenitor cells from the bone
marrow.
The potential role of inflammatory and angiogenic mediators in
modulating progenitor cell numbers cannot be disregarded.
Furthermore, levels of cytokines such as VEGF can differ
according to tissue location and disease stage [40;41]. Increased
levels of VEGF are associated with an increased production and
mobilization of progenitor cells from the bone marrow [39],
whereas TNF-a may impair its production [42;43]. In this study,
both plasma levels of VEGF and TNF-a were increased in the
COPD group, as compared with the non-smokers, as in previous
studies [14;44]. However, the enhanced levels of VEGF did not
correlate with the increased numbers of circulating progenitor
cells.
The concurrence of reduced numbers of circulating progenitor
cells and elevated plasma levels of VEGF and TNF-a have also
been reported in other conditions where systemic inflammation
may contribute to vascular impairment, as in rheumatoid arthritis
[39] or congestive heart failure [45]. Interestingly, treatment with
TNF-a blockers increases the number of circulating progenitor
cells and enhances their endothelial differentiation [39]. Accord-
ingly, there may be a connection between systemic inflammation
and CD45+CD34+CD133+ count reduction in COPD, where
TNF-a might play a pivotal role [43].
Whatever the mechanism accounting for circulating progenitor
cell reduction in COPD, it is interesting to note that in our series
COPD patients with PH had greater numbers of circulating
progenitor cells than those without suspected PH. This might
suggest that these patients may preserve to some extent the bone
marrow capacity to mobilize these cells in response to lung
vascular injury.
Both COPD patients and healthy smokers showed impaired
endothelial function when compared with non-smokers, in
agreement with previous studies [15;16;20]. COPD patients also
showed a trend towards reduced endothelium-independent
vasodilation, suggesting that vascular abnormalities in COPD
may not be restricted to the endothelium and affect also smooth
muscle cells [20]. Furthermore, the baseline brachial artery
diameter was greater in healthy smokers and in COPD patients.
Differences in vessel size could be explained by fibrous remodeling
of the media in large arteries that may result in vessel stiffness and
dilatation [20].
Endothelial function of systemic arteries was inversely related to
the number of circulating progenitor cells in COPD patients,
being the patients with lesser flow-mediated dilation those with
greater number of circulating progenitor cells. This finding agrees
with the observation of greater CD45+CD34+CD133+ numbers in
COPD patients with suspected PH, suggesting that vascular
damage, either in the pulmonary or the systemic circulation, might
stimulate the bone marrow and promote the release of progenitor
cells. This data contrasts with what has been observed in healthy
individuals with different degrees of cardiovascular risk, where
endothelial function was directly related to the number of
circulating progenitors [8].
Interestingly, healthy smokers showed similar endothelial
dysfunction in the brachial artery than COPD patients, but the
number of circulating CD45+CD34+CD133+ was significantly
increased compared to COPD patients and unrelated to the
endothelial function. This suggests that endothelial dysfunction
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and changes in progenitor cell numbers may follow different
pathways in COPD. Presumably, endothelial dysfunction results
from the effect of cigarette smoke products on endothelial cells,
likely as a result of oxidative stress [46], whereas the impaired
release of bone marrow-derived progenitor cells may result from
mechanisms not linked to cigarette consumption and likely related
to changes induced by the disease itself.
In the present series, COPD patients had increased levels of IL-
6, hsCRP, VEGF, TNF-a and fibrinogen, compared with non-
smokers. Healthy smokers also had higher levels of IL-6,
fibrinogen, angiopoietin-2 and TNF-a than non-smokers. No
correlation was found between the number of circulating
CD45+CD34+CD133+, systemic endothelial function and any of
these biomarkers. This is consistent with recent studies [14;20;44]
and denotes the complex interactions between markers of systemic
inflammation and vascular impairment.
This study has some limitations. Firstly, the study population
was carefully selected to avoid any cardiovascular risk factor other
than cigarette smoking. This is not representative of the common
COPD population since these patients usually present additional
factors for cardiovascular risk. Nevertheless, the absence of
cardiovascular risk factors allowed us to avoid potential confound-
ing factors on the pathogenesis of endothelial dysfunction and
impaired release of progenitors in COPD. Secondly, we did not
investigate the dynamics of circulating progenitor cells and thus we
cannot report on whether observed differences reflect alterations
in progenitor cell mobilization, survival or tissue uptake. Thirdly,
events in systemic circulation such as reduced levels of progenitor
cells may not necessarily reflect changes in the lung tissue. Finally,
PH was assessed by echocardiography in most patients and only a
few patients had PH diagnosed by right heart catheterization.
Despite we took into account recent recommendations on the
predictive diagnostic value of echocardiography for PH [25], we
cannot discard that some of our cases with suspected PH would be
false positives or in the other hand, patients without suspected PH
would be false negatives. Given the purposes of the present
investigation, it was considered not appropriate to perform right
heart catheterization to subclassify COPD patients.
In summary, the present study shows that circulating hemato-
poietic progenitor cells are reduced in COPD which seems to be
independent of the smoking habit. This suggests that lower
number of progenitor cells is probably caused by factors related to
the disease itself, presumably systemic inflammation. Yet, COPD
patients have preserved capacity to mobilize progenitor cells, as
suggested by the observation that those with greater vascular
damage, either at the pulmonary or the systemic circulation, have
higher numbers of circulating CD45+CD34+CD133+ cells. We
have also shown that cigarette smoking plays a key role in
endothelial dysfunction, which is present in both healthy smokers
and COPD patients. The association of endothelial dysfunction
and impaired repair capacity, as a consequence of reduced
progenitor cell mobilization, may contribute to the cardiovascular
comorbidity frequently shown in COPD, especially if additional
risk factors concur.
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